title: [The study of dynamics of clinical and molecular phenotypes in the generalized form of myasthenia with optimized and combined treatment].
abstract: The aim of the study was the research of clinical and molecular phenotypes in the generalized form of myasthenia with optimized treantment, which includes the application of basic mode of the treatment and meglumine sodium succinate, and also the combined mode of the treatment, which includes the mode of the treatment and meglumine sodium succinate and ozonotherapy. The most epressed improvement of indicators of the clinical and neurologic status (the eliminaton of motoring breakdown, eye movement disrders, the weaknesses of mimic, respiratory and chewing muscles, bulbar syndrome, the doubling in eye and ptosis, pharyngeal violations and increase in volume of movement of eyes) was observed in the group of patients receiving the combined therapy. The reduction of the epressiveness of the defeat of the neuromotor device and the decrement of the amplitude of the various degree of M-answer in patients with myasthenla is revealed in the application of the combined therapy in the comparison with the application of the basic and optimized therapy. For the first time we have investigaed the dynamics of the intensity of the expression of specfic peptides and proteins in blood serum in patients with the application of basic therapy, reamberin and ozonotherapy, which have allowed to open the new mechanisms of the efficiency ofthe combined therapy of the disease.
authors.forename: O A
authors.initials: OA
authors.lastname: Drozd
authors.forename: V V
authors.initials: VV
authors.lastname: Efremov
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: I V
authors.initials: IV
authors.lastname: Sarvilina
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000493:pharmacokinetics; D001682:Biological Availability; D003131:Combined Modality Therapy; D004576:Electromyography; D005260:Female; D006801:Humans; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008875:Middle Aged; D015166:Monitoring, Immunologic; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010126:Ozone / Q000008:administration & dosage / Q000493:pharmacokinetics; D040901:Proteomics; D015398:Signal Transduction / Q000187:drug effects; D013385:Succinate Dehydrogenase / Q000378:metabolism*; D013386:Succinates / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; C549374:Reamberin; D013386:Succinates; D010126:Ozone; D008536:Meglumine; D013385:Succinate Dehydrogenase